Objective:
To evaluate the effects of flexible dosing of aflibercept 8 mg in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME) who had prior treatment and ongoing disease activity.
Key Findings:
- Vision gain of up to 3 letters in both wet AMD and DME cohorts, statistically significant.
- Reduction in retinal thickness by approximately 32 µm in AMD and up to 50 µm in DME, indicating effective treatment.
Interpretation:
The ELARA study indicates that flexible dosing of aflibercept 8 mg can lead to significant vision improvements and reduced retinal thickness in patients with ongoing disease activity despite prior anti-VEGF treatment, suggesting potential changes in clinical practice.
Limitations:
- Data presented is from the first 417 eyes at 24 weeks; long-term outcomes are still pending, necessitating caution in interpretation.
Conclusion:
The findings from the ELARA study provide promising evidence for the use of flexible aflibercept dosing in challenging cases of wet AMD and DME.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
